Abstract Library

#2810 Development of a Personalized Human Immunocompetent Ex-Vivo Model of Neuroendocrine Liver Metastasis Using Precision Cut Tissue Slice Technology

Introduction: Liver metastasis (LM) are very frequent (65-95%) and represent a crucial prognostic factor in patients with gastroenteropancreatic neuroendocrine neoplasms (GEP NENs). The paucity of relevant experimental models has limited the understanding of the pathophysiology of NENs and the development of efficient therapeutic strategies

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Doornebal E

Authors: Doornebal E, Harris N, Miquel R, Zen Y, Pizanias M,

Keywords: Liver, neuroendocrine liver metastasis, ex-vivo model, personalized medicine, immunocompetent, organotypic tissue slices,

#1772 Expression of Truncated Functional Subtype 5 Somatostatin Receptor Variant (sst5TMD4) in GEP-NETs and Association with Relevant Pathways Involved in NET Tumorigenesis

Introduction: Sst5TMD4, which is derived from a non-canonical splicing process of sst5 receptor, is overexpressed in several endocrine tumors and associated with a worse prognosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Diaz Perez A, Martínez-Fuentes A, García-Carbonero R, Luque R, Jimenez-Fonseca P,

Keywords: somatostatin receptor, neuroendocrine tumors,

#1742 Nucleolin (NCL) Regulates Aerobic Glycolysis in Pancreatic Neuroendocrine Tumor (p-NET) BON-1 Cells

Introduction: NCL, a nucleolus localized protein and ribosomal RNA (rRNA) expression regulator, has been reported to function as an oncogene in several tumors. However, the expression and role of NCL in p-NET remains unclear.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Jin K, Yu X,

Keywords: pancreatic neuroendocrine tumors (p-NETs), Nucleolin (NCL), ribosomal RNA, ATP, aerobic glycolysis,

#1462 Cross-Talk Between EGFR and IGF1R Influences the Response to RTK Inhibitors in Bronchopulmonary (BP)-NET Cell Lines

Introduction: BP-NETs represent ~30% of all neuroendocrine tumors. BP-NET treatment is challenging due to onset of resistance to chemo and targeted therapies. EGFR and IGF1R had been associated with tumor onset and progression in several neoplasia.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Gagliano T

Authors: Gagliano T, Gentilin E, Benfini K, Falletta S, Di Pasquale C,

Keywords: BP-NET RTK,

#1173 Investigation of the Effects of Sunitinib on Pheochromocytoma and Paraganglioma Primary Cultures

Introduction: The main treatment for Pheochromocytoma and Paraganglioma is surgery. However these tumors are highly vascularized, suggesting the possible role for anti-angiogenic agents in the medical therapy. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor (TKI), mainly described to inhibit VEGFR

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Bellio M, Gagliano T, Feo C, Balboni F, Gentilin E,

Keywords: Sunitinib, Pheochromocytoma, Paraganglioma ,